Published in Hepatology on December 01, 2007
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol (2014) 2.86
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut (2014) 1.91
Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol (2011) 1.70
Hepatic fibrosis. Curr Opin Gastroenterol (2009) 1.67
Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology (2008) 1.40
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther (2007) 1.33
Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology (2008) 1.23
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology (2010) 1.20
Hepatic stellate cells: partners in crime for liver metastases? Hepatology (2011) 1.17
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology (2011) 1.17
Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int (2011) 1.12
Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis. Lab Invest (2010) 1.10
The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology (2012) 1.07
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol (2009) 1.07
Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol (2012) 1.05
Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol (2014) 1.04
Intracellular calcium signals regulate growth of hepatic stellate cells via specific effects on cell cycle progression. Cell Calcium (2009) 1.00
Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis. Hepatology (2010) 0.98
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death Dis (2013) 0.98
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol (2010) 0.97
Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med (2008) 0.97
Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer (2013) 0.96
Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol (2010) 0.96
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One (2011) 0.92
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest (2010) 0.92
Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol (2012) 0.91
Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment. Am J Physiol Gastrointest Liver Physiol (2010) 0.91
Reversal of liver fibrosis. Saudi J Gastroenterol (2009) 0.90
The lung in liver disease: old problem, new concepts. Trans Am Clin Climatol Assoc (2013) 0.89
The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis. Evid Based Complement Alternat Med (2012) 0.88
Vascular factors, angiogenesis and biliary tract disease. Curr Opin Gastroenterol (2010) 0.88
The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS One (2014) 0.87
Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. J Cell Mol Med (2012) 0.86
Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. PLoS One (2014) 0.85
Promising Therapy Candidates for Liver Fibrosis. Front Physiol (2016) 0.85
Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs. Am J Pathol (2011) 0.83
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks. PLoS One (2015) 0.83
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PLoS One (2013) 0.83
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol (2015) 0.82
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials. Front Pharmacol (2016) 0.81
Systems level analysis and identification of pathways and networks associated with liver fibrosis. PLoS One (2014) 0.81
Peritoneal morphologic changes in a peritoneal dialysis rat model correlate with angiopoietin/Tie-2. Pediatr Nephrol (2008) 0.81
Pathophysiology of portal hypertension and its clinical links. J Clin Exp Hepatol (2011) 0.79
Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. PLoS One (2013) 0.78
Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. PLoS One (2013) 0.78
New therapies for hepatic fibrosis. Clin Res Hepatol Gastroenterol (2015) 0.78
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. Int J Nanomedicine (2012) 0.78
PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr (2015) 0.78
New Developments on the Treatment of Liver Fibrosis. Dig Dis (2016) 0.77
Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. PLoS One (2016) 0.77
Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol (2015) 0.76
Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol (2016) 0.76
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J (2015) 0.75
Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis (2016) 0.75
Yiguanjian decoction and its ingredients inhibit angiogenesis in carbon tetrachloride-induced cirrhosis mice. BMC Complement Altern Med (2015) 0.75
Canonical hedgehog signaling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis. Br J Pharmacol (2017) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis. Biomed Res Int (2017) 0.75
Participation of aquaporin-1 in vascular changes and remodeling in cirrhotic liver. Med Mol Morphol (2013) 0.75
Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf) (2017) 0.75
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg (2008) 5.94
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (2003) 3.66
Role of a research ethics committee in follow-up and publication of results. Lancet (2003) 3.61
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology (2010) 3.45
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 2.83
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci (2002) 2.49
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology (2002) 2.34
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol (2012) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology (2008) 2.04
Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology (2012) 2.03